Evaluation of Urine Tumor-Associated Trypsin Inhibitor, CYFRA 21-1, and Urinary Bladder Cancer Antigen for Detection of High-Grade Bladder Carcinoma

Urology

Volumn 72, Issue 5, 2008, Pages 1159-1163

  Gkialas, Ioannis ^a   Papadopoulos, Georgios ^a   Iordanidou, Lydia ^b   Stathouros, Georgios ^a   Tzavara, Chara ^c   Gregorakis, Alkiviadis ^d   Lykourinas, Michael ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CYTOKERATIN 19 FRAGMENT; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; EVALUATION; HUMAN; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 54849422411     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.04.009     Document Type: Article

References (23)

1. Black R.J., Bray F., Ferlay J., et al. Cancer incidence and mortality in the European Union: Cancer registry and estimates of national incidence for 1990. Eur J Cancer 33 (1997) 991-996
2. Raghavan D., Shipley W.U., Garnick M.B., et al. Biology and management of bladder cancer. N Engl J Med 322 (1990) 1129-1138
3. Foresman W.H., and Messing E.M. Bladder cancer: Natural history, tumor markers and early detection strategies. Semin Surg Oncol 13 (1997) 299-306
4. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urinary markers for bladder cancer surveillance: A systematic review. Eur Urol 47 (2005) 736-748
5. Wiener H.G., Mian C., Haitel A., et al. Can urinary bound diagnostic tests replace cystoscopy in the management of bladder cancer?. J Urol 159 (1998) 1876-1880
6. van der Poel H.G., and Debruyne F.M. Can biological markers replace cystoscopy?. An update. Curr Opin Urol 11 (2001) 503-509
7. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109-118
8. Sobin D.H., and Witteking C. TNM Classification of Malignant Tumours. 6th ed. (2003), Wiley-Liss, New York 199-202
9. Saad A., Hanbury D.C., McNicholas T.A., et al. The early detection and diagnosis of bladder cancer: A critical review of the options. Eur Urol 39 (2001) 619-633
10. Epstein J.I., Amin M.B., Reuter V.R., et al., Bladder Consensus Conference Committee. The World Health Organisation/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22 (1998) 1435-1448
11. Hakenberg O.W., Fuessel S., Richter K., et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 64 (2004) 1121-1126
12. Sanchez-Carbayo M., Espasa A., Chinchilla V., et al. New electrochemiluminiscent immunoassay for the determination of CYFRA 21-1: Analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45 (1999) 1944-1953
13. Pariente J.L., Bordenave L., Michel P., et al. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 158 (1997) 338-341
14. Nisman B., Barak V., Shapiro A., et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 94 (2002) 2914-2922
15. Mian C., Lodde M., Haitel A., et al. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55 (2000) 223-226
16. Stenman U.H., Huhtala M.L., Koistinen R., et al. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 30 (1982) 53-57
17. Huhtala M.L., Pesonen K., Kalkkinen N., et al. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257 (1982) 13713-13716
18. Diggle C.P., Cruickshank S., Olsburgh J.D., et al. Identification of genes up-regulated in urothelial tumors: The 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 163 (2003) 493-504
19. Pectasides D., Bafaloucos D., Antoniou F., et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 19 (1996) 271-277
20. Hotakainen K., Bjartell A., Sankila A., et al. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 28 (2006) 95-101
21. Kelloniemi E., Rintala E., Finne P., et al. Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62 (2003) 249-253
22. Shariat S.F., Herman M.P., Casella R., et al. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48 (2005) 424-431
23. Stenman U.H., Koivunen E., Itkonen O., et al. Tumor-associated trypsin inhibitor, TATI: Clinical use and biological function. Ann Chir Gynaecol 78 (1989) 77-82